Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that
Read MoreThe nation’s largest ketamine therapy provider now offers complimentary patient resources supporting holistic mental health treatment. On Thursday, the largest ketamine therapy
Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat